Text/Yangcheng Evening News All Media Reporter Zhang Hua
Recently, the reporter learned from the Guangdong Provincial Drug Administration that according to the “Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Supervision Innovation and Development Work Plan” and “Guangdong Drug and Medical Device Supervision and Development Work Plan” According to the requirements of the Interim Regulations on the Administration of Drugs and Medical Devices Imported from Hong Kong and Macao in Urgent Clinical Needs in the Guangdong-Hong Kong-Macao Greater Bay Area content.
At present, I have used the “Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Supervision Innovation and Development Work Plan”, and 6 drugs have been approved at the University of Hong Kong Shenzhen Hospital , Zhuhai Xima Lin Shunchao Eye Hospital, Guangzhou Modern Hospital use. Among them, the non-small cell lung cancer drug capmatinib was approved for use in Guangzhou Modern Hospital.
It is understood that the “Hong Kong-Macao Pharmaceutical Machinery” policy allows drugs and medical devices that have been listed in Hong Kong and Macao, are widely used in public hospitals, and are urgently needed in clinical or mainland China. In August last year, the number of pilot hospitals was expanded to 5, namely Guangzhou United Family Hospital, Guangzhou Modern Hospital, Zhongshan Chen Xinghai Hospital, Zhuhai Xima Lin Shunchao Eye Hospital and Hong Kong University Shenzhen Hospital.
New drugs bring new clinical solutions to patients
Under the impetus of policies, capmatinib is not approved by the US FDA. In two years, he entered Guangzhou to provide innovative treatment solutions for lung cancer patients.
According to the “2020 Latest Global Cancer Burden Data” released by the World Health Organization’s International Agency for Research on Cancer (IARC), the incidence and mortality of lung cancer, the largest cancer in China, ranks first in the world, and new cases are As high as nearly 820,000, the death toll exceeded 710,000, accounting for 23.8% of the total cancer deaths in the country.
Relevant studies have shown that many lung cancers are associated with METex14 (METex14) skipping mutations and EGFR, ALK, HER2 and other gene mutations. Among them, the mutation rate of METex14 skipping mutation in advanced non-small cell lung cancer is about 3%-4%.
Professor Liu Junling from the Department of Medical Oncology, Sun Yat-Sen University Cancer Hospital pointed out in an interview with reporters: “At this stage, the traditional treatment methods for METex14 non-small cell lung cancer in China include chemotherapy, multi-target tyrosine kinase inhibitors. and immunotherapy, etc., but the benefit of patients is limited, and there is an urgent need for drugs that can break through conventional treatment and more effective treatment methods. Capmatinib has been preferentially recommended by the international guidelines for lung cancer for the treatment of METex14 exon skipping patients. The full-line treatment of small cell lung cancer has brought new clinical solutions to these patients, and it has been launched in Hong Kong, China, the United States, Japan, Brazil, etc. This time, it can be introduced into cities in the Greater Bay Area, so that the majority of patients can better The convenient use of innovative drugs is undoubtedly a great news.”
Capmatinib inhibits mutations and brings breakthroughs in lung cancer treatment
This Capmatinib, which was launched in the Greater Bay Area, is an oral drug that can effectively inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce cell apoptosis to achieve anti-tumor activity.
Professor Liu Junling introduced that the results of the study showed that the effective rates of capmatinib in the treatment of advanced non-small cell lung cancer patients with METex14 skipping mutation were 66.7% and 44%, respectively, and the median overall survival was 66.7% and 44%. The time (OS) was 20.8 months and 13.6 months.
That is to say, patients with advanced non-small cell lung cancer with METex14 skipping mutation, especially untreated patients, can obtain better therapeutic effect by choosing capmatinib.
At present, the non-small cell lung cancer drug capmatinib has been successfully included in the second batch of catalogues of medicines and medical devices urgently needed to be imported from Hong Kong and Macao in the Guangdong-Hong Kong-Macao Greater Bay Area. The urgent clinical diagnosis and treatment needs of metastatic non-small cell lung cancer patients with exon 14 (METex14) skipping mutation allow patients in the Guangdong-Hong Kong-Macao Greater Bay Area and even the whole country to simultaneously use the high-quality drugs that have been marketed in Hong Kong and Macao, benefiting from the global precise treatment. (For more news, please pay attention to Yangcheng Pie pai.ycwb.com)